Health
Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential
July 24, 2025
In this episode of Psychedelics Today, Joe Moore sits down with Alan Davis, Associate Professor at Ohio State University, to explore the evolving landscape of Ibogaine research and its therapeutic potential.
In this episode of Psychedelics Today, Joe Moore sits down with Alan Davis, Associate Professor at Ohio State University, to explore the evolving landscape of Ibogaine research and its therapeutic potential.
Alan offers a deep dive into the Iboga Patient Survey, a groundbreaking initiative collecting real-world data on the safety and efficacy of Ibogaine—particularly for those struggling with substance use disorders and mental health challenges. The conversation sheds light on the need for rigorous, community-informed research that could pave the way toward FDA approval and increased access for patients, including veterans dealing with trauma.
They also discuss the complexities of clinical trials, the tension between state and federal regulations, and the growing influence of corporate interests in psychedelic research. Alan emphasizes the importance of ethical transparency, community collaboration, and maintaining scientific integrity as the field grows.
If you’re curious about the intersection of psychedelic medicine, clinical research, and patient safety, this is a must-listen episode.
Topics Covered
- 00:00 – Introduction and Guest Welcome
- 00:53 – Reflecting on COVID-19’s Psychological Impact
- 01:29 – Introducing the Iboga Patient Survey
- 01:46 – History and Goals of Ibogaine Research
- 02:41 – Challenges in Conducting Clinical Trials
- 03:14 – Importance of Real-World Safety Data
- 06:55 – Personal Interest in Ibogaine
- 08:56 – Veterans and Trauma: A Personal Connection
- 10:53 – Reintegration and Emotional Processing
- 15:29 – Survey Participation and Accessibility
- 18:25 – Building Partnerships and Overcoming Challenges
- 21:06 – Ensuring Safety and Transparency
- 31:49 – Community and Academic Collaboration
- 33:06 – Survey Design and Future Research Directions
- 36:50 – Momentum in Psychedelic Research
- 37:48 – State vs. Federal Regulation
- 39:23 – Challenges in Psychedelic Treatment
- 43:01 – Corporate Interests and Scientific Objectivity
- 47:20 – Ketamine and Collaborative Research
- 51:56 – Ibogaine Patient Survey
- 57:55 – Psychedelics and Pain Research
- 01:07:22 – Conclusion and Future Directions
